The thoracic oncology community is discussing several trial results. In ES-SCLC, a study of consolidation thoracic radiotherapy showed no PFS or OS benefit and was stopped for toxicity. In NSCLC, the phase 3 ZEAL-1L trial of niraparib plus pembrolizumab maintenance was negative, and a secondary analysis of LIBRETTO-431 found no benefit from adding pembrolizumab to chemotherapy for RET fusion-positive patients. A business development is also noted: a deal to bring the EGFR exon 20 inhibitor sunvozertinib to the US.
“No benefit in PFS or OS with consolidation XRT vs atezo alone. Trial stopped early due to toxicity.”
— @TejasPatilMD · SCLC Radiotherapy · View post ↗📌 Amplified by @KolPulseAI
“Negative results from phase 3 ZEAL-1L trial @JTOonline. Pts with NSCLC completed induction chemo-immunotherapy, randomized to pembro maintenance with PARP inhibitor niraparib or placebo.”
— @StephenVLiu · ZEAL-1L Trial · View post ↗“FINALLY! AstraZeneca reaches deal with Dizal to bring sunvozertinib to the US! Approved for EGFR exon 20 NSCLC over a year ago but only available in China (and at a different dose).”
— @StephenVLiu · Sunvozertinib Access · View post ↗📌 Amplified by @KolPulseAI
“A secondary analysis of LIBRETTO-431 found no significant differences in PFS or OS between chemoimmunotherapy (n=83) and chemotherapy alone (n=19).”
— @UOzkerim · LIBRETTO-431 Analysis · View post ↗The breast oncology community is discussing the Phase 3 SERENA-6 trial, which showed that using ctDNA to detect an ESR1 mutation and switching to the SERD camizestrant before radiological progression significantly improved PFS in HR+/HER2- advanced breast cancer. Other topics include a Phase I/II trial of 3-fraction accelerated partial breast irradiation (Tri-APBI) for early-stage disease and the long-term risk of distant recurrence in premenopausal patients.
“New in #practicalRO: Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer.”
— @ASTRO_org · Accelerated Partial Breast Irradiation · View post ↗
“SERENA-6 Phase 3: Switching to camizestrant upon ctDNA-detected ESR1 mutation BEFORE progression (1L HR+/HER2- advanced BC) → Median PFS: 16.8 vs 9.2 months (HR 0.45) → Also significant PFS2 benefit”
— @drnurullahilhan · SERENA-6 trial results · View post ↗📌 Amplified by @KolPulseAI
“From Radiologic to Molecular Progression—ctDNA Guided Camizestrant Switching at ESR1 Mutation Emergence Significantly Improves PFS and PFS2, Defining a New Precision Oncology Paradigm in HR+/HER2 Advanced #BreastCancer.”
— @Dr_Oncologista · ctDNA-guided therapy · View post ↗
“This is really important. Too many docs and patients underestimate the long term risk for distant recurrence in breast cancer. In premenopausal breast cancer these risk are VERY high.”
— @Dr_RShatsky · Recurrence risk · View post ↗The GI oncology community is discussing a potential breakthrough in pancreatic cancer. Other topics include translational research on how steatosis shapes liver metastasis heterogeneity in colorectal cancer, and a multicenter study suggesting staging laparoscopy may improve surgical outcomes for intrahepatic cholangiocarcinoma.
“⭐️A breakthrough in pancreatic cancer has experts excited and braced for what’s to come”
— @VivekSubbiah · Pancreatic Cancer · View post ↗“Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC”
— @VivekSubbiah · Colorectal Cancer Metastasis · View post ↗
“Why can Hepatocellular Carcinoma (HCC) often be diagnosed without a biopsy, while most other cancers cannot? The answer lies in its unique vascular transformation.”
— @DrRupamOncology · HCC Diagnostics · View post ↗
“A multicenter study suggests staging laparoscopy may improve surgical outcomes and overall survival in patients with intrahepatic cholangiocarcinoma.”
— @HepatomaRes · Intrahepatic Cholangiocarcinoma Surgery · View post ↗Discussion in GU oncology includes a new approval for enfortumab vedotin plus pembrolizumab for the perioperative treatment of bladder cancer. In renal cell carcinoma (RCC), topics include investigational approaches such as a CAIX-targeted imaging tracer for staging, the validation of KIM-1 as a biomarker, and adjuvant treatment decisions post-nephrectomy.
“An important approval for EV pembro for periop treatment of bladder cancer!”
— @TiansterZhang · Bladder cancer approval · View post ↗
“Staging kidney cancer with FDG PET has never really worked. A tracer aimed at CAIX, the antigen clear cell RCC almost always expresses, just showed why a target-specific approach fits the biology better.”
— @katy_beckermann · RCC imaging · View post ↗
“Validating biomarkers in clinical trials takes monumental effort, but it’s key to optimizing patient outcomes.”
— @yao_zhu_sh · RCC biomarkers · View post ↗The myeloma/hematology community is discussing two new meta-analyses. One systematic review of 1,900 patients confirmed high activity for BCMA- and GPRC5D-directed bispecific antibodies in RRMM, with an overall response rate of 65.9% and median PFS of 8.8 months. A separate CAR-T analysis of over 7,600 patients found a non-relapse mortality rate of 6.8%, with the highest rate for ciltacel (15%). Also noted was the FDA's acceptance of the new drug application for mezigdomide based on SUCCESSOR-2 results.
“✅ ORR: 65.9% ✅ ≥VGPR: 51.0% ✅ ≥CR: 38.2% ✅ Median PFS: 8.8 months These results reinforce bispecific antibodies as an effective off-the-shelf immunotherapy option.”
— @Abdallah81MD · Bispecific antibody efficacy · View post ↗
“The @US_FDA accepted the new drug application for #mezigdomide in combination with #carfilzomib and #dexamethasone for relapsed or refractory multiple #myeloma following positive phase 3 #SUCCESSOR2 results.”
— @MyelomaTeacher · Mezigdomide regulatory update · View post ↗📌 Amplified by @KolPulseAI
“Future studies should focus on: ✅ Head-to-head comparisons ✅ Biomarker-driven patient selection ✅ Optimal sequencing after CAR-T or prior bispecific therapy ✅ Strategies to reduce infections and prolonged cytopenias.”
— @Abdallah81MD · Bispecific antibody future directions · View post ↗The hematology community is discussing the final analysis of the phase 3 SYMPATICO study, which evaluated ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma. Also trending is the recent approval of imetelstat, a first-in-class telomerase inhibitor for transfusion-dependent anemia in MDS. Other topics include the integration of radiation with bispecific antibodies in B-cell lymphoma and a case report of a secondary T-cell lymphoma following bispecific CAR-T therapy.
“Today I learned about imetelstat, a first in class telomerase inhibitor approved for transfusion-dependent anemia caused by MDS.”
— @allisonoconn · Imetelstat approval in MDS · View post ↗
“Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.”
— @geltamo · SYMPATICO study in MCL · View post ↗
“New #JITC case report: "Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy"”
— @jitcancer · CAR-T secondary malignancy · View post ↗